ヒト化genO-hIgE/hFcεR1マウスモデル

The humanized genO‑hCD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

‍

Triple-humanized genO‑hCD47/hSIRPα/hFcγR immunocompetent mice enable the in vivo efficacy and safety assessment of anti-CD47/SIRPα antibodies with a competent or engineered Fc region.

‍

Preclinical humanized Fc-gamma receptor (genO‑hFcγR) model enabling the in vivo assessment of Fc receptor-targeted therapies.

‍

Double-humanized genO‑hFcγR/hFcRn mouse model to improve PK and efficacy assessment of compounds with extended half-life through FcRn binders.

‍

Double-humanized genO-hFcγR/hIgG1 mouse model to improve the tolerability to human IgG1 therapeutic antibodies.

‍

Double humanized genO‑hSA/hFcRn mouse model as a cutting-edge platform for preclinical development of hSA (hALB) and FcRn-oriented therapeutics.

This upgraded, immunocompromised RAG1^-/- version of our genO-hSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

Double-humanized genO-hTFRC/hFcγR mouse model to improve biodistribution and enable drug shuttling through the blood-brain barrier (BBB) by binding to human human TFRC (CD71, TfR1).

‍

The genO‑hTNF-α model provides new opportunities for in vivo assessment of anti-TNF therapies.